Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q3 2020 · 10-Q
Revenue$4.40M$4.40M−16.8% vs Q3 2019 Net Income-$1.08M-$1.08MN/M vs Q3 2019 EPS Diluted-$0.72-$0.72N/M vs Q3 2019 Gross Profit$2,001,000−29.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Operating Cash Flowderived-$840,000N/M Free Cash Flowderived-$849,000N/M Margins · derivedGross margin45.5%−8.4 pt vs Q3 2019
Operating margin-25.2%+19.3 pt vs Q3 2019
Net margin-24.7%+18.9 pt vs Q3 2019
ended Dec 31, 2019 · filed Feb 14, 2020 · 45 d after period end